Levi & Korsinsky, LLP announces that a AKBA class action lawsuit has been filed on behalf of investors who purchased Akebia Therapeutics, Inc. (AKBA) securities between June 28, 2018 and September 2, 2020. For more on the AKBA Lawsuit please contact us today.
According to the Akebia Therapeutics, Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
(i) the Company’s lead investigational product candidate, vadadustat, was not as safe in treating non-dialysis dependent chronic kidney disease patients with anemia as defendants had represented; (ii) as a result, defendants overstated the clinical prospects of a Phase 3 clinical program for vadadustat; (iii) accordingly, defendants also overstated vadadustat’s overall commercial and regulatory prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Akebia Therapeutics, Inc. you have until May 13, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.